Comparison of the Performance of the PanBio COVID-19 Antigen Test in SARS-CoV-2 B.1.1.7 (Alpha) Variants versus non-B.1.1.7 Variants
| Autor: | D Eggink, T J W van de Laar, M L van Ogtrop, W A van der Reijden, Joost W. Vanhommerig |
|---|---|
| Přispěvatelé: | Medical Microbiology and Infection Prevention |
| Rok vydání: | 2021 |
| Předmět: |
Microbiology (medical)
Coronavirus disease 2019 (COVID-19) Physiology Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) B.1.1.7 variant Alpha (ethology) Antibodies Viral Microbiology Sensitivity and Specificity Virus COVID-19 Serological Testing antigen Antigen Genetics diagnostics Medicine Humans Antigens Viral Netherlands General Immunology and Microbiology Ecology business.industry Diagnostic Tests Routine SARS-CoV-2 COVID-19 Cell Biology Viral Load Antigen test Virology QR1-502 Rapid identification Infectious Diseases business Viral load Research Article |
| Zdroj: | Microbiology Spectrum Microbiology Spectrum, Vol 9, Iss 3 (2021) Microbiology spectrum, 9(3):e00884. American Society for Microbiology |
| ISSN: | 2165-0497 |
| Popis: | This study evaluates the performance of the PanBio COVID-19 antigen (Ag) test as part of a hospital infection control policy. Hospital staff was encouraged to get tested for COVID-19 when presenting with SARS-CoV-2-related symptoms. In a period of approximately 5 months, a steady decline in the performance of the Ag test was noted, epidemiologically coinciding with the rise of the SARS-CoV-2 B.1.1.7 (alpha) variant of concern (VOC) in the Netherlands. This led to the hypothesis that the diagnostic performance of the PanBio COVID-19 Ag test was influenced by the infecting viral variant. The results show a significantly lower sensitivity of the PanBio COVID-19 Ag test in persons infected with the B.1.1.7 (alpha) variant of SARS-CoV-2 in comparison with that in persons infected with non-B.1.1.7 variants, also after adjustment for viral load. IMPORTANCE Antigen tests for COVID-19 are widely used for rapid identification of COVID-19 cases, for example, for access to schools, festivals, and travel. There are several FDA- and CE-cleared tests on the market. Their performance has been evaluated mainly on the basis of infections by the classical variant of the causing virus, SARS-CoV-2. This paper provides evidence that the performance of one of the most widely used antigen tests detects significantly fewer cases of COVID-19 by the alpha variant than by the classical variants of SARS-CoV-2. This means that the role of antigen tests needs to be reevaluated in regions where other variants of SARS-CoV-2 predominate. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|